Back to search results

Empagliflozin for Heart Failure Risk in Adults with High Blood Pressure

This study is looking at whether empagliflozin, a medication originally for type 2 diabetes, can improve the function of the left atrium (a chamber of the heart) in adults at risk for heart failure. You might be able to join if you are over 60, have high blood pressure (hypertension), and have a body mass index (BMI) of 30 or higher. The study aims to see how empagliflozin affects left atrial function after 9 months. This trial is currently unclear on its recruitment status, but plans to enroll 80 participants.

Study design
This interventional study plans to enroll 80 participants to compare empagliflozin to a placebo (an inactive pill).
What's involved
At Visit 1, after randomization, you will receive a 3-month supply of either empagliflozin or a placebo to take daily.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, change in left atrial function, will be measured at 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06507657

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

Recruiting
EARLY_PHASE1Ages 60+InterventionalTreatment
University of Minnesota
~80 participants
Updated 2025-10-03 on ClinicalTrials.gov
What's tested:empagliflozinPlacebo tablet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
change in LA function
Measured over 9 months

Conditions

Hypertension
Cardiovascular Diseases

Explore related trials

Cardiovascular DisorderHypertension

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Jeremy Van't Hof, MD · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Julie Dicken, RN
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>60 years of age
Clinical diagnosis of hypertension
Body mass index ≥30kg/m2
We will screen for participants with an echocardiogram within 60 days of the baseline visit

Exclusion

Female participants who are pregnant, lactating, or of child bearing potential
History of type 1 or type 2 diabetes mellitus by medical history or hemoglobin A1c \>7.0% at Visit 1
Clinical diagnosis of HFpEF or HFrEF by participant self-report or documented in the electronic health record
Any LVEF measure of ≤40% on past echocardiogram
Moderate or severe valve disease on echocardiogram
History of genitourinary infection
eGFR \<60 ml/min/1.73 m2 at Visit 1
Current treatment with SGLT2 inhibitor, GLP1 agonist, or DPP4 inhibitors
Participants in whom coronary revascularization by either PCI or bypass surgery is being contemplated within 6 months, or who have undergone revascularization in the prior 2 months
Significant allergy or known intolerance to SGLT2 inhibitors or any ingredient in the formulations
Participants currently experiencing any clinically significant or unstable medical condition that might limit their ability to complete the study, or to comply with the requirements of the protocol, including: dermatologic disease, hematological disease, pulmonary disease, hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease, and psychiatric disease
Any malignancy not considered cured (except basal cell carcinoma of the skin). A participant is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening
Participants who have participated in studies of an investigational drug or device within 30 days prior to the screening visit
Inadequate quality echocardiographic images
Unstable coronary syndromes
Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1 or scheduled major elective surgery within 90 days after Visit 1.
Non-English speaking individuals

What this trial measures

  • change in LA function9 months

    LA function will be quantified by assessing LA reservoir, conduit, and contractile strain with 2DE at baseline and 9 months.